Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07049276 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Multicentre Selective Lymphadenectomy Trial - 3

Study acronym: MSLT-3
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 7 to 8v8
  2. Study sites: 6 to 7v7
  3. Re-verified, no change to tracked fieldsv6
  4. Secondary endpoints: details revised at 2 of 13 entriesv5
  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 2025 to Oct 1, 2025 · Site details revised at 6 of 6 sitesv4 Show 2 more changesShow less
    • Start date changed from estimate of Oct 2025 to Oct 1, 2025
    • Site details revised at 6 of 6 sites
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Aug 2025 to Oct 2025v3
  2. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to demonstrate that there is no difference (non-inferiorty) in the 2 year recurrence-free survival (RFS) between 2 different surgical approaches for clinical Stage III melanoma. Following 6 weeks of standard neaodjuvant immunotherapy, patients will undergo either selective index lymph node resection (ILN) (identified at baseline as the largest affected lymph node) or the standard of care therapeutic lymph node dissection (TLND). The secondary aims are to assess if patients who are managed without TLND will have a reduction in surgical complications (less wound problems \& lymphoedema), an improved quality of life, at a lower healthcare utilisation.
Trial Details
NCT Number NCT07049276
Lead Sponsor Melanoma Institute Australia
Conditions Cutaneous Melanoma, Stage III
Enrollment 1,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov